Second-Line Therapy in Advanced HCC: Treatment Considerations and Evolving Options
Panelists discuss how, when a patient progresses to second-line therapy, key considerations include prior treatment response, toxicity, patient comorbidities, and therapeutic goals. Lenvatinib shows potential beyond first-line treatment, offering efficacy in patients progressing on systemic therapies, with emerging data supporting its role in treatment sequencing.
Video content above is prompted by the following:
- What treatment considerations arise when a patient progresses and requires second-line therapy?
- Discuss the potential for lenvatinib beyond first-line treatment in patients progressing on systemic therapies.
Recent Videos
Related Content
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024Article
During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
